Dose Insider / Glossary / Subcutaneous injection

Subcutaneous injectionWhere GLP-1 shots go and why sites rotate

Updated November 20, 2026 · 3 min read · MedlinePlus SQ injections; Wegovy, Saxenda, Victoza and Zepbound labels

A subcutaneous injection, often written SQ or sub-Q, is a shot given into the fatty tissue just under the skin, rather than into a muscle or a vein.1 GLP-1 injections are given this way: the labels of Wegovy, Saxenda, Victoza and Zepbound all say to inject under the skin of the abdomen, the thigh or the upper arm.2,3,4

3 inUpper arm, Below the shoulder, at least, distances to keep
Distances to keepWhere to place a shot under the skin, inchesUPPER ARMBelow the shoulder, at least3 inAbove the elbow, at least3 inBELLYFrom the belly button, at least2 inROTATIONBetween one shot and the next1 inDistances to keepWhere to place a shot under the skin, inchesUPPER ARMBelow the shoulder, at least3 inAbove the elbow, at least3 inBELLYFrom the belly button, at least2 inROTATIONBetween one shot and the next1 in

General guidance; a pen's own instructions come first.

On this page

Where the shot goes

MedlinePlus, the National Library of Medicine's health site, gives the boundaries of each area for anyone injecting under the skin:1

The skin at the site should be healthy, with no redness, swelling, scarring or bruising. MedlinePlus advises changing the site from one injection to the next, at least 1 inch apart, to keep the skin healthy and help the medicine absorb well.1 For tirzepatide, the label gives the share of a dose that reaches the blood as 80%, with no difference between the three areas.4

From under the skin into the blood

A shot under the skin is absorbed slowly, which suits medicines meant to last. The Wegovy label says 89% of a semaglutide dose reaches the blood and the highest level comes 1 to 3 days after the shot. Exposure was similar whether the shot went into the abdomen, the thigh or the upper arm.2 Liraglutide, taken once a day, peaks sooner: the Saxenda label puts the highest level at 11 hours after the shot.3

Why the site rotates

The Saxenda and Victoza labels add a specific reason. They advise rotating sites within the same region to reduce the risk of cutaneous amyloidosis, a skin condition listed among the reactions reported after approval.3,5 The labels also say no change in dose is needed when switching the site or the time of day.3 Our page on Zepbound injection sites covers the three areas in detail.

How the needle goes in

For a shot with a syringe, MedlinePlus describes pinching about an inch, or 2.5 cm, of skin and fat, not muscle, and inserting the needle all the way at a 90-degree angle, or 45 degrees if there is little fat.1 GLP-1 pens come with their own instructions for use, which take precedence. A few rules apply to every device:

MedlinePlus, subcutaneous (SQ) injections.1

Reactions at the site

Redness, itching or a small lump where the needle went in are the usual reactions. In the weight-loss trials behind the Wegovy label, 1.4% of people on Wegovy and 1% on placebo had injection site reactions, including itching, redness, inflammation, hardening and irritation.2 They were more common on Zepbound: 6% on 5 mg and 8% on 10 and 15 mg, against 2% on placebo. Among people who developed antibodies to tirzepatide, 11.3% had a reaction at the site, against 1% of those who did not.4

Serious allergic reactions are a different matter. The Wegovy label reports anaphylaxis and angioedema and says that if such a reaction occurs, the medicine should be stopped and treated promptly.2

Sources

  1. MedlinePlus. Subcutaneous (SQ) injections. A.D.A.M. Medical Encyclopedia; review date October 19, 2025, read November 20, 2026. medlineplus.gov
  2. WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; sections 2, 5, 6 and 12.3. dailymed.nlm.nih.gov
  3. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version 22, published June 15, 2026; sections 2, 6.2 and 12.3. dailymed.nlm.nih.gov
  4. ZEPBOUND (tirzepatide) prescribing information, Medication Guide and Instructions for Use, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2.4, 5.6, 5.10, 6.1 and 12.3, Table 1. accessdata.fda.gov
  5. VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version 31, published November 17, 2025; sections 2 and 6.2. dailymed.nlm.nih.gov

Related analyses

Log the site of each shot, so you can rotate and spot a spot that reacts.

Open Dose Insider